Edition:
United States

Kazia Therapeutics Ltd (KZIA.OQ)

KZIA.OQ on NASDAQ Stock Exchange Capital Market

2.30USD
3:59pm EST
Change (% chg)

$-0.27 (-10.51%)
Prev Close
$2.57
Open
$2.50
Day's High
$2.50
Day's Low
$2.30
Volume
2,214
Avg. Vol
1,141
52-wk High
$7.56
52-wk Low
$2.30

Summary

Name Age Since Current Position

Iain Ross

2017 Non-Executive Chairman of the Board

James Garner

43 2016 Chief Executive Officer, Executive Director

Bryce Carmine

2016 Non-Executive Deputy Chairman of the Board

Gordon Hirsch

2016 Chief Medical Officer

Lilischkis Kimberley

Clinical & Regulatory Affairs Manager

Peng Leong

2016 Chief Business Officer

Stephen Palmer

2014 Program Director - Degenerative Diseases

Justine Stehn

2014 Director - ATM Program

Kate Hill

2016 Interim Company Secretary

Steven Coffey

2012 Non-Executive Director

Biographies

Name Description

Iain Ross

Mr. Iain Ross is Non-Executive Chairman of the Board of the Company. Benitec Biopharma Ltd. and Tissue Therapies Ltd. Following a career with multinational companies Sandoz AG, Fisons plc, Hoffman La Roche and Celltech Group plc, he has for approximately 20 years undertaken a number of company start-ups, turnarounds and exits as a board member on behalf of private equity groups and banks. These include Quadrant Healthcare PLC (sold to Elan); Eden BioDesign (sold to Watson Pharmaceuticals); Phadia AB - formerly Pharmacia Diagnostics (sold to Cinven); SR Pharma PLC (merged with Atugen AG to form Silence Therapeutics PLC which was then merged with Intradigm Inc); Allergy Therapeutics Limited (prepared for IPO) and Ark Therapeutics PLC (sold subsidiaries off to private equity).

James Garner

Dr. James B. Garner is Chief Executive Officer, Executive Director of the Company. Garner brings broad experience in drug development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector. His previous responsibilities have included leading non-clinical safety and efficacy, phase I-IV clinical trials, product registration, reimbursement, medical marketing and business development. Dr Garner is currently Head of the Unit Development Office, AP R&D with Sanofi and is based in Singapore . Dr Garner is currently Head of the Unit Development Office, AP R&D with Sanofi and is based in Singapore . He will relocate to Sydney in the New Year. After qualifying in medicine at Imperial College in London , Dr Garner spent several years as a practicing clinician in the UK and Australia before joining Bain & Company, a global management consulting company in 2002. He subsequently worked with Biogen and Progen Pharmaceuticals in Australia and with Quintiles, an international clinical research organisation in Singapore . In 2009, he was appointed Regional Vice President for Takeda Pharmaceutical Company with overall responsibility for all clinical development activities and registration of new chemical entities in the Asian region (excluding Japan ), and served as General Manager of the company's regional R&D Hub in Singapore . In mid-2013, Dr Garner took up his current role at Sanofi. Aside from his medical qualifications, Dr Garner holds a BSc (with First Class Honours) from University College London, an MA in Philosophy and an MBA from the University of Queensland , and a postgraduate qualification in Applied Finance & Investment from the Financial Services Institute of Australasia. In 2008, he was named a 'Young Executive of the Year' by the Australian Financial Review 's BOSS Magazine.

Bryce Carmine

Mr. Bryce Carmine is Non-Executive Deputy Chairman of the Board of the Company. He has 36 years’ experience with one of the world’s largest pharmaceutical companies where he held numerous roles including Executive Vice President for Eli Lilly & Co, and President, Lilly Bio Medicines business unit. For much of that time, as a senior executive, he was responsible for Eli Lilly’s global late-stage drug development pipeline. Mr Carmine holds US residency and brings to the Board a strong understanding of the drug development process and dynamics of the pharmaceutical industry. He will continue to Chair the Board’s Scientific Committee. Mr Carmine is currently Chairman and CEO of a Sydney-based biotechnology company, HaemaLogiX. He holds a B.Sc. in biochemistry from Massey University in New Zealand.

Gordon Hirsch

Dr. Gordon Hirsch is the Chief Medical Officer of the Company. Dr Hirsch has spent almost twenty years in the pharmaceutical industry where he has worked with Pfizer Inc (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), Sanofi SA (NYSE: SNY), and The Takeda Pharmaceutical Company (TYO: 4502). His career has involved a broad range of global responsibilities, stretching from early development to commercialisation, and including appointments in Australia, Japan, France, and the United States, and encompassing a portfolio of products with global sales in the billions of dollars. He holds a medical degree from the University of the Witwatersrand in South Africa, and an MBA from Henley Business College in the UK. Dr Hirsch will be based in Sydney, Australia.

Lilischkis Kimberley

Ms. Lilischkis Kimberley is a Clinical & Regulatory Affairs Manager of the company., She was Clinical Research and Regulatory Manager with extensive scientific research training. She has clinical trials management knowledge and experience in both the academic research environment and industry. Her scientific research career spans more than 20 years in both clinical and laboratory research areas in Australia and Europe. Kimberley has a focused interest in oncology research and the translation of new findings into improved health outcomes for cancer patients.

Peng Leong

Mr. Peng K. Leong is the Chief Business Officer of the Company. Dr Peng Leong will join the company as Chief Business Officer, commencing in September. Dr Leong will be primarily responsible for identifying and negotiating in-licensing and out-licensing opportunities for Novogen, and will take a central role in the ongoing development and execution of Novogen's corporate strategy. Dr Leong has spent eighteen years in the pharmaceutical industry, beginning as a scientist, and followed by eight years in healthcare investment banking and private equity, and eight years in business development. Dr Leong started his career at Chiron Corporation, a pioneering biotechnology company based in California that was subsequently acquired by Novartis International AG (NYSE: NVS). While working in healthcare investment banking at CIBC World Markets and Piper Jaffray, he was involved in raising more than US$ 1.4 billion for over 20 biotechnology companies. In his various roles, including his most recent position at Merck Serono (FWB: MRK), Dr Leong has had a leadership role in the acquisition or sale of over US$ 1 billion in pharmaceutical product rights. He holds a PhD in Biochemistry from the University of Toronto, Canada and an MBA from the University of California, Berkeley. Dr Leong will be based in Cambridge, Massachusetts. In addition to these senior management appointments, Novogen has bolstered its operational capabilities by hiring David Cain, formerly of Aviragen Therapeutics Inc (NASDAQ: AVIR), previously known as Biota Pharmaceuticals. Mr Cain will join Novogen as Director of Chemistry, Manufacturing, and Controls (CMC) and will commence work with the company in October.

Stephen Palmer

Mr. Stephen Palmer is a Program Director - Degenerative Diseases of the company., Since 2014 and is responsible for running the drug discovery programme centred around stimulating regenerative processes in stem cells and developing novel therapies for degenerative diseases including dementia, muscular dystrophy, lysosomal storage disorders and autoimmune disease. Dr Palmer completed his PhD in 1992 at University College London and established a career studying the genetic regulation of embryonic development and inherited disorders. Using genetically modified mice as models of human disease, he has studied normal and abnormal cellular function in several different organ systems. Dr Palmer migrated to Australia on a Wellcome Trust International Travelling Fellowship and worked at the Victor Chang Cardiac Research Institute and the Children’s Medical Research Institute in Sydney. He established a research program on the neurodevelopmental disorder Williams-Beuren syndrome, demonstrating the key role of the GTF2IRD1 protein. He currently holds a conjoint Senior Lectureship at UNSW Australia.

Justine Stehn

Dr. Justine R. Stehn, Ph.D., is Director - ATM Program of Novogen Ltd effective February 3, 2014. Prior to joining the Company, She is responsible for the drug development of the ATM program, which was acquired by Novogen in 2013 and Dr Stehn is also the co-inventor. Dr Stehn has over 20 years research experience in understanding the role of the cell cytoskeleton in disease. After receiving her PhD from the Garvan Institute of Medical Research, Sydney, Justine was awarded a prestigious National Health and Medical Research Council (NHMRC), CJ Martin Fellowship to support her post doctoral positions at Harvard University and the Centre for Cancer Research at the Massachusetts Institute of Technology (MIT), Boston, USA.

Kate Hill

Steven Coffey

Mr. Steven Roy Stent Coffey is Non-Executive Director of the Company. He is a chartered accountant, having spent his career in public practice since graduating from University of New South Wales in 1983. He has been a partner in the chartered accounting firm Watkins Coffey Martin since 1993. He is a registered company auditor and audits a number of large private companies as well as a number of not-for-profit entities. He has previously served on the board of an Australian listed public company. He is currently a board member of private family foundation.

Basic Compensation